Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Canadian Solar Inc CSIQ

Canadian Solar Inc. is a Canada-based solar technology and renewable energy company. The Company is a manufacturer of solar photovoltaic modules, a provider of solar energy and battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects with a geographically diversified pipeline in various stages of development. It operates through two... see more

NDAQ:CSIQ - Post Discussion

Canadian Solar Inc > Anal Fissure Treatment Market, Share, Analysis 2022-2031
View:
Post by robertpears on Aug 04, 2022 9:46am

Anal Fissure Treatment Market, Share, Analysis 2022-2031

Kenneth Research published a report titled Anal Fissure Treatment Market: Global Demand Analysis & Opportunity Outlook 2031” which delivers a detailed overview of the Global Anal Fissure Treatment Market in terms of market segmentation by treatment type, route of administration, end-user, distribution channel, and by region.

Further, for an in-depth analysis, the report encompasses the industry growth indicators, restraints, and supply and demand risk, along with a detailed discussion of the current and future market trends that are associated with the growth of the market.

The global anal fissure treatment market is estimated to attain significant revenue by growing at a noteworthy CAGR of about ~7% over the forecast period, i.e., 2022 –  2031. The growth of the market can be attributed to the expanding pediatric and geriatric patient pool with a high incidence of constipation, adoption of unhealthy lifestyle choices among the global population, advances in technology, and the availability of multiple treatment options. The popularity of over-the-counter (OTC) drugs may spur market growth owing to the need for immediate relief.

Request A Free Sample PDF of this Report: https://www.kennethresearch.com/sample-request-10082826

The global anal fissure treatment market is segmented and analyzed for demand and supply by route of administration into oral and topical. Oral treatment options are expected to grow during the forecast period as many of these medications are easily available over the counter.  Laxatives are oral medicines that are widely used to treat Constipation in Children. Globally, around 30% of children suffer from bouts of constipation which is projected to drive the market growth.
 
Regionally, the global anal fissure treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds a larger share in the global anal fissure treatment market because of its growing geriatric population. People aged 65 and up made up 16.6% of the US population in 2019 and are expected to make up 21.6 percent by 2040, according to the Administration for Community Living.
User image

Asia-Pacific has the fastest growing market due to the presence of a large number of generic manufacturers, and the advent of new products into the market by the emerging pharmaceutical and biotechnological industries. The National Investment Promotion & Facilitation Agency reports that the pharmaceutical industry in India produces around 60,000 generic brands, including generic drugs, OTC Medicines, API/Bulk Drugs, and others across 60 therapeutic segments.

The research is global in nature and covers a detailed analysis of the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of the Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook, etc. have also been covered and displayed in the research report.

Access Full Report Here: https://www.kennethresearch.com/report-details/anal-fissure-treatment-market/10082826

High Incidence of Constipation to Drive Market Growth

The majority of anal fissures occur at either the posterior or anterior midline of the anus. They are most common in patients with a history of constipation and are classified as acute (lasting less than six weeks) or chronic (lasting more than six weeks). Constipation is common among all ages and populations in the United States. About 16 out of 100 adults and about 33 out of 100 adults aged 60 and older have symptoms of constipation, according to a study conducted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
However, the high costs associated with the surgery as well as some of the side effects of the drugs used for the treatment are expected to operate as key restraints to the growth of the anal fissure treatment market over the forecast period.

This report also provides the existing competitive scenario of some of the key players in the global anal fissure treatment market which includes company profiling of AstraZeneca, SLA Pharma AG, Eisai Co., Ltd., Bayer AG, Novasep, Ipsen,  Cipla Inc., SRS Life Sciences, Healthy Life Pharma Private Limited, Geri-Care Pharmaceuticals Corp., and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials, and recent news and developments. On the whole, the report depicts a detailed overview of the global anal fissure treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching for possibilities, and other stakeholders to align their market-centric strategies according to the ongoing and expected trends in the future. 
    
Request To Download Sample of This Strategic Report: https://www.kennethresearch.com/sample-request-10082826


Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates, and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided the right guidance at the right time is available through strategic minds. Our out-of-box thinking helps our clients to take wise decisions in order to avoid future uncertainties.
Contact for more Info:
AJ Daniel
Email: sales@kennethresearch.com
U.S. Phone: +1 313 462 0609

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities